Alternative
|
Incremental cost-effectiveness ratioa
|
Incremental net benefits ($)
|
---|
LOW
|
LMI
|
UMI
|
HIGH
|
LOW
|
LMI
|
UMI
|
HIGH
|
All
|
---|
OPV23 cessation in 2017
|
CLS
|
CLS
|
CLS
|
CLS
|
0.3
|
3.0
|
2.7
|
1.3
|
7.3
|
OPV123 cessation in 2018
|
CLS
|
CLS
|
CLS
|
1.9
|
300
|
660
|
190
|
−8.6
|
1,100
|
OPV123 cessation in 2019
|
Dominated
|
Dominated
|
Dominated
|
Dominated
|
−0.3
|
−2.6
|
−1.6
|
0
|
−4.6
|
OPV123 cessation in 2019 with tOPV-only from 2017
|
Dominated
|
Dominated
|
Dominated
|
Dominated
|
−0.3
|
−2.5
|
−1.6
|
0
|
−4.5
|
OPV123 cessation in 2019 with IPV added from 2018
|
CSLC
|
CSLC
|
CSLC
|
Dominated
|
110
|
370
|
380
|
0
|
860
|
- Abbreviations: HIGH, high-income; IPV, inactivated poliovirus vaccine; LMI, lower middle-income; LOW, low-income; OPV, oral poliovirus vaccine; OPV(##) cessation, globally-coordinated cessation of OPV containing the serotype(s) indicated by ##; UMI, upper middle-income; $, 2013 United States dollar
- aNumbers represent millions of $ per disability-adjusted life-year averted; Letters are: CLS, cost and life-saving (i.e., negative incremental costs and positive cases prevented); CSLC cost-saving but life-costing (i.e., positive incremental costs and negative cases prevented); Dominated, positive incremental costs and negative cases prevented